Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A

NCT01458106 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

DRUG: BIIB031 (rFVIIIFc)
DRUG: FVIII (PK subgroup only)

Sponsor

Bioverativ Therapeutics Inc.

Collaborators

[object Object]